< Back to situations

[ORGANIZATION]

GLP-1 medications

Featured in 5 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

259 clusters · 928 sources · last updated

Latest: Medical experts warn of weight regain risks for GLP-1 users

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[QUIET] [BUSINESS] [US]

Corporate GLP-1 medication coverage trends

3 clusters · 9 sources · last updated

Latest: Bank of America maintains GLP-1 coverage for obesity

Major U.S. employers are adopting diverging strategies regarding the coverage of GLP-1 weight-loss medications, such as Ozempic, Wegovy, and Zepbound, due to rising costs. Bank of America has committed over $250 million

Also covered in